BACKGROUND: Delirium occurs frequently in the intensive care unit (ICU), but its pathophysiology is still unclear. Low levels of insulin-like growth factor 1 (IGF-1), a hormone with neuroprotective properties, have been associated with delirium in some non-ICU studies, but this relationship has not been examined in the ICU. We sought to test the hypothesis that low IGF-1 concentrations are associated with delirium during critical illness. METHODS: Mechanically ventilated medical ICU patients were prospectively enrolled, and blood was collected after enrollment for measurement of IGF-1 using radioimmunometric assay. Delirium and coma were identified daily using the Confusion Assessment Method for the ICU and the Richmond Agitation-Sedation Scale, respectively. The association between IGF-1 and delirium was evaluated with logistic regression. In addition, the association between IGF-1 and duration of normal mental state, measured as days alive without delirium or coma, was assessed using multiple linear regression. RESULTS: Among 110 patients, the median age was 65 years (IQR, 52-75) and APACHE II was 27 (IQR, 22 -32). IGF-1 levels were not a risk factor for delirium on the day after IGF-1 measurement (p = 0.97), at which time 65% of the assessable patients were delirious. No significant association was found between IGF-1 levels and duration of normal mental state (p = 0.23). CONCLUSIONS: This pilot study, the first to investigate IGF-1 and delirium in critically ill patients, found no association between IGF-1 and delirium. Future studies including serial measurements of IGF-1 and IGF-1 binding proteins are needed to determine whether this hormone has a role in delirium during critical illness.
BACKGROUND:Delirium occurs frequently in the intensive care unit (ICU), but its pathophysiology is still unclear. Low levels of insulin-like growth factor 1 (IGF-1), a hormone with neuroprotective properties, have been associated with delirium in some non-ICU studies, but this relationship has not been examined in the ICU. We sought to test the hypothesis that low IGF-1 concentrations are associated with delirium during critical illness. METHODS: Mechanically ventilated medical ICU patients were prospectively enrolled, and blood was collected after enrollment for measurement of IGF-1 using radioimmunometric assay. Delirium and coma were identified daily using the Confusion Assessment Method for the ICU and the Richmond Agitation-Sedation Scale, respectively. The association between IGF-1 and delirium was evaluated with logistic regression. In addition, the association between IGF-1 and duration of normal mental state, measured as days alive without delirium or coma, was assessed using multiple linear regression. RESULTS: Among 110 patients, the median age was 65 years (IQR, 52-75) and APACHE II was 27 (IQR, 22 -32). IGF-1 levels were not a risk factor for delirium on the day after IGF-1 measurement (p = 0.97), at which time 65% of the assessable patients were delirious. No significant association was found between IGF-1 levels and duration of normal mental state (p = 0.23). CONCLUSIONS: This pilot study, the first to investigate IGF-1 and delirium in critically illpatients, found no association between IGF-1 and delirium. Future studies including serial measurements of IGF-1 and IGF-1 binding proteins are needed to determine whether this hormone has a role in delirium during critical illness.
Authors: Seema Basi; Lara B Pupim; Edith M Simmons; M Tugrul Sezer; Yu Shyr; Stephanie Freedman; Glenn M Chertow; Ravindra L Mehta; Emil Paganini; Jonathan Himmelfarb; T Alp Ikizler Journal: Am J Physiol Renal Physiol Date: 2005-04-19
Authors: Pratik P Pandharipande; Brenda T Pun; Daniel L Herr; Mervyn Maze; Timothy D Girard; Russell R Miller; Ayumi K Shintani; Jennifer L Thompson; James C Jackson; Stephen A Deppen; Renee A Stiles; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: JAMA Date: 2007-12-12 Impact factor: 56.272
Authors: Alix Ashare; Amanda B Nymon; Kevin C Doerschug; John M Morrison; Martha M Monick; Gary W Hunninghake Journal: Am J Respir Crit Care Med Date: 2008-04-24 Impact factor: 21.405
Authors: Timothy D Girard; John P Kress; Barry D Fuchs; Jason W W Thomason; William D Schweickert; Brenda T Pun; Darren B Taichman; Jan G Dunn; Anne S Pohlman; Paul A Kinniry; James C Jackson; Angelo E Canonico; Richard W Light; Ayumi K Shintani; Jennifer L Thompson; Sharon M Gordon; Jesse B Hall; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: Lancet Date: 2008-01-12 Impact factor: 79.321
Authors: Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon Journal: Best Pract Res Clin Endocrinol Metab Date: 2011-10 Impact factor: 4.690
Authors: Babar A Khan; Anthony J Perkins; Nagendra K Prasad; Anantha Shekhar; Noll L Campbell; Sujuan Gao; Sophia Wang; Sikandar H Khan; Edward R Marcantonio; Homer L Twigg; Malaz A Boustani Journal: Crit Care Med Date: 2020-03 Impact factor: 7.598
Authors: Cristiane Ritter; Cristiane D Tomasi; Felipe Dal-Pizzol; Bernardo Bollen Pinto; Alex Dyson; Aline S de Miranda; Clarissa M Comim; Márcio Soares; Antonio L Teixeira; João Quevedo; Mervyn Singer Journal: Crit Care Date: 2014-05-23 Impact factor: 9.097
Authors: Timothy E Yen; John C Allen; Sarah K Rivelli; Stephanie C Patterson; Meredith R Metcalf; Benjamin J Flink; Aibek E Mirrakhimov; Sandhya A Lagoo; Thomas P Vail; Christopher C Young; Richard E Moon; Paula T Trzepacz; Madan M Kwatra Journal: Sci Rep Date: 2016-02-05 Impact factor: 4.379